Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era.
作者信息
Mato Anthony, Jahnke Jordan, Li Pengxiang, Mehra Maneesha, Ladage Vrushabh P, Mahler Michelle, Huntington Scott, Doshi Jalpa A
机构信息
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA.
出版信息
Haematologica. 2018 Oct;103(10):e462-e465. doi: 10.3324/haematol.2017.185868. Epub 2018 Apr 26.
Abstract
摘要
相似文献
1
Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era.新型药物时代之前老年慢性淋巴细胞白血病患者的真实世界治疗及转归
Haematologica. 2018 Oct;103(10):e462-e465. doi: 10.3324/haematol.2017.185868. Epub 2018 Apr 26.
2
Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.在不适合接受氟达拉滨、环磷酰胺和利妥昔单抗（FCR）方案的老年晚期慢性淋巴细胞白血病患者中，作为一线治疗方案，加用个体化剂量来那度胺联合苯丁酸氮芥和利妥昔单抗的可行性和疗效。
Haematologica. 2019 Jan;104(1):147-154. doi: 10.3324/haematol.2018.193854. Epub 2018 Aug 16.
3
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab.idelalisib-利妥昔单抗治疗复发/难治性慢性淋巴细胞白血病患者生存风险评分（SRS）的验证
Blood Cancer J. 2020 Sep 16;10(9):92. doi: 10.1038/s41408-020-00358-3.
4
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.bax/bcl-2比值在慢性淋巴细胞白血病中的临床意义
Haematologica. 2016 Jan;101(1):77-85. doi: 10.3324/haematol.2015.131854. Epub 2015 Nov 12.
5
Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis.老年患者是否足以作为慢性淋巴细胞白血病临床试验中苯丁酸氮芥对照组的依据：一项监测、流行病学和最终结果（SEER）医保分析
Leukemia. 2023 Jul;37(7):1558-1560. doi: 10.1038/s41375-023-01915-y. Epub 2023 May 23.
6
Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.利妥昔单抗联合苯达莫司汀或苯丁酸氮芥治疗慢性淋巴细胞白血病：随机、开放标签 MABLE 研究的主要分析。
Haematologica. 2018 Apr;103(4):698-706. doi: 10.3324/haematol.2017.170480. Epub 2018 Feb 1.
7
Altered treatment of chronic lymphocytic leukemia in Germany during the last decade.德国过去十年中慢性淋巴细胞白血病治疗方法的改变。
Ann Hematol. 2016 May;95(6):853-61. doi: 10.1007/s00277-016-2640-z. Epub 2016 Mar 29.
8
A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.一线治疗慢性淋巴细胞白血病的无进展生存期和总生存期的网状荟萃分析。
Cancer Treat Rev. 2015 Feb;41(2):77-93. doi: 10.1016/j.ctrv.2014.11.004. Epub 2014 Dec 4.
9
Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.低剂量氟达拉滨和环磷酰胺联合标准剂量利妥昔单抗（LD-FCR）治疗老年初治慢性淋巴细胞白血病患者安全有效：以色列 CLL 研究组经验。
Hematol Oncol. 2019 Apr;37(2):185-192. doi: 10.1002/hon.2580. Epub 2019 Mar 12.
10
Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.奥妥珠单抗作为慢性淋巴细胞白血病的一线治疗：CLL11研究的更新结果。
Leukemia. 2015 Jul;29(7):1602-4. doi: 10.1038/leu.2015.14. Epub 2015 Jan 30.
引用本文的文献
1
Cost impact of Bruton's tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia.布鲁顿酪氨酸激酶抑制剂的选择对医疗保险慢性淋巴细胞白血病患者的费用影响
J Comp Eff Res. 2025 Jun 23:e250035. doi: 10.57264/cer-2025-0035.
2
Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US.美国慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者的治疗模式、医疗资源利用情况和成本。
Oncologist. 2024 Mar 4;29(3):e360-e371. doi: 10.1093/oncolo/oyad324.
3
Real-World Evidence on the Clinical Characteristics and Management of Patients with Chronic Lymphocytic Leukemia in Spain Using Natural Language Processing: The SRealCLL Study.利用自然语言处理技术获取西班牙慢性淋巴细胞白血病患者临床特征与治疗的真实世界证据：SRealCLL研究
Cancers (Basel). 2023 Aug 10;15(16):4047. doi: 10.3390/cancers15164047.
4
Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to Cyclophosphamide.利妥昔单抗偶联纳米粒靶向沉默 NRF2 增加慢性淋巴细胞白血病细胞对环磷酰胺的敏感性。
Cell Commun Signal. 2023 Aug 1;21(1):188. doi: 10.1186/s12964-023-01213-1.
5
Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review.复发难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的当前治疗选择：综述。
Curr Treat Options Oncol. 2023 Sep;24(9):1259-1273. doi: 10.1007/s11864-023-01112-0. Epub 2023 Jul 6.
6
The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.布鲁顿激酶抑制剂在慢性淋巴细胞白血病中的作用：现状与未来方向
Cancers (Basel). 2022 Feb 2;14(3):771. doi: 10.3390/cancers14030771.
7
Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries.在全国 Medicare 受益人群样本中，新开始使用的口服抗癌药物的治疗利用模式。
J Manag Care Spec Pharm. 2021 Oct;27(10):1457-1468. doi: 10.18553/jmcp.2021.27.10.1457.
8
Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population.接受系统治疗的慢性淋巴细胞白血病患者的总生存期、不良事件和经济负担：来自医疗保险人群的真实世界证据。
Cancer Med. 2021 Apr;10(8):2690-2702. doi: 10.1002/cam4.3855. Epub 2021 Mar 18.
9
The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites.康奈克特慢性淋巴细胞白血病注册研究：对美国199个地点的1494例慢性淋巴细胞白血病患者的最终分析。
Blood Adv. 2020 Apr 14;4(7):1407-1418. doi: 10.1182/bloodadvances.2019001145.
10
Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes.伊布替尼相关的慢性淋巴细胞白血病患者的关节痛/肌痛：发生率及其对临床结局的影响。
Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):438-444.e1. doi: 10.1016/j.clml.2020.02.001. Epub 2020 Feb 27.
本文引用的文献
1
Economic Modeling of the Cost of Chronic Lymphocytic Leukemia Therapy: It Is About the Model.慢性淋巴细胞白血病治疗成本的经济模型：关键在于模型本身。
J Clin Oncol. 2017 Jun 1;35(16):1863-1864. doi: 10.1200/JCO.2016.71.9690. Epub 2017 Mar 13.
2
Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.老年慢性淋巴细胞白血病的特征与预后评估：对美国455例接受治疗患者的前瞻性评估
BMC Cancer. 2017 Mar 16;17(1):198. doi: 10.1186/s12885-017-3176-x.
3
Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force.老年慢性淋巴细胞白血病（CLL）的管理：国际老年肿瘤学会（SIOG）工作组的立场文件。
Ann Oncol. 2017 Feb 1;28(2):218-227. doi: 10.1093/annonc/mdw547.
4
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.一线苯达莫司汀和利妥昔单抗联合化疗与氟达拉滨、环磷酰胺和利妥昔单抗治疗晚期慢性淋巴细胞白血病（CLL10）患者：一项国际、开放标签、随机、III 期、非劣效性临床试验。
Lancet Oncol. 2016 Jul;17(7):928-942. doi: 10.1016/S1470-2045(16)30051-1. Epub 2016 May 20.
5
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.伊布替尼作为慢性淋巴细胞白血病患者的初始治疗方法。
N Engl J Med. 2015 Dec 17;373(25):2425-37. doi: 10.1056/NEJMoa1509388. Epub 2015 Dec 6.
6
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.开发一种用于慢性淋巴细胞白血病患者的综合预后指数。
Blood. 2014 Jul 3;124(1):49-62. doi: 10.1182/blood-2014-02-556399. Epub 2014 May 5.
7
Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database.老年慢性淋巴细胞白血病患者的治疗实践——SEER 与医疗保险数据库的联合分析。
Ann Hematol. 2014 Aug;93(8):1335-44. doi: 10.1007/s00277-014-2048-6. Epub 2014 Mar 18.
8
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.奥滨尤妥珠单抗联合苯丁酸氮芥治疗伴有合并症的 CLL 患者。
N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8.
9
An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia.一项观察性研究，评估在 Medicare 诊断为慢性淋巴细胞白血病的患者中初始输注治疗后的结局。
Blood. 2011 Mar 31;117(13):3505-13. doi: 10.1182/blood-2010-08-301929. Epub 2010 Dec 29.
10
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.利妥昔单抗联合氟达拉滨和环磷酰胺治疗慢性淋巴细胞白血病患者的随机、开放标签、3 期临床试验。
Lancet. 2010 Oct 2;376(9747):1164-74. doi: 10.1016/S0140-6736(10)61381-5.
Zotero 插件